Clinuvel Pharmaceuticals Dirección
Dirección controles de criterios 3/4
El CEO de Clinuvel Pharmaceuticals' es Philippe Wolgen , nombrado en Nov 2005, tiene una permanencia de 18.42 años. compensación anual total es A$6.39M, compuesta por 24.9% salario y 75.1% primas, incluidas acciones y opciones de la empresa. posee directamente un 6.84% de las acciones de la empresa, por valor de A$48.81M. La antigüedad media del equipo directivo y de la junta directiva es de 11.6 años y 7.8 años, respectivamente.
Información clave
Philippe Wolgen
Chief Executive Officer (CEO)
AU$6.4m
Compensación total
| Porcentaje del salario del CEO | 24.9% |
| Permanencia del CEO | 18.5yrs |
| Participación del CEO | 6.8% |
| Permanencia media de la dirección | 11.7yrs |
| Promedio de permanencia en la Junta Directiva | 6.3yrs |
Actualizaciones recientes de la dirección
Recent updates
If EPS Growth Is Important To You, Clinuvel Pharmaceuticals (ASX:CUV) Presents An Opportunity
Aug 11
Calculating The Intrinsic Value Of Clinuvel Pharmaceuticals Limited (ASX:CUV)
Jun 27Is Now The Time To Put Clinuvel Pharmaceuticals (ASX:CUV) On Your Watchlist?
May 09Estimating The Intrinsic Value Of Clinuvel Pharmaceuticals Limited (ASX:CUV)
Mar 24An Intrinsic Calculation For Clinuvel Pharmaceuticals Limited (ASX:CUV) Suggests It's 41% Undervalued
Nov 18Increases to Clinuvel Pharmaceuticals Limited's (ASX:CUV) CEO Compensation Might Cool off for now
Oct 20Is Clinuvel Pharmaceuticals Limited (ASX:CUV) Trading At A 21% Discount?
Jul 30Clinuvel Pharmaceuticals Limited (ASX:CUV) Shares Could Be 27% Below Their Intrinsic Value Estimate
Feb 27Does Clinuvel Pharmaceuticals (ASX:CUV) Deserve A Spot On Your Watchlist?
Dec 14This Is The Reason Why We Think Clinuvel Pharmaceuticals Limited's (ASX:CUV) CEO Might Be Underpaid
Nov 03A Look At The Fair Value Of Clinuvel Pharmaceuticals Limited (ASX:CUV)
Sep 23Here's Why I Think Clinuvel Pharmaceuticals (ASX:CUV) Might Deserve Your Attention Today
Jul 23With EPS Growth And More, Clinuvel Pharmaceuticals (ASX:CUV) Is Interesting
Apr 10Have Insiders Sold Clinuvel Pharmaceuticals Limited (ASX:CUV) Shares Recently?
Mar 06Earnings Miss: Clinuvel Pharmaceuticals Limited Missed EPS By 41% And Analysts Are Revising Their Forecasts
Feb 27What Is The Ownership Structure Like For Clinuvel Pharmaceuticals Limited (ASX:CUV)?
Feb 20Clinuvel Pharmaceuticals (ASX:CUV) Shareholders Have Enjoyed A Whopping 648% Share Price Gain
Feb 01Estimating The Fair Value Of Clinuvel Pharmaceuticals Limited (ASX:CUV)
Jan 14We Wouldn't Rely On Clinuvel Pharmaceuticals's (ASX:CUV) Statutory Earnings As A Guide
Dec 28
Clinuvel Pharmaceuticals Limited's (ASX:CUV) Stock's On An Uptrend: Are Strong Financials Guiding The Market?
Dec 10What You Need To Know About Clinuvel Pharmaceuticals Limited's (ASX:CUV) Investor Composition
Nov 21Análisis de compensación del CEO
| Fecha | Compensación total | Salario | Ingresos de la empresa |
|---|---|---|---|
| Dec 31 2023 | n/a | n/a | AU$30m |
| Sep 30 2023 | n/a | n/a | AU$30m |
| Jun 30 2023 | AU$6m | AU$2m | AU$31m |
| Mar 31 2023 | n/a | n/a | AU$29m |
| Dec 31 2022 | n/a | n/a | AU$26m |
| Sep 30 2022 | n/a | n/a | AU$24m |
| Jun 30 2022 | AU$7m | AU$1m | AU$21m |
| Mar 31 2022 | n/a | n/a | AU$22m |
| Dec 31 2021 | n/a | n/a | AU$24m |
| Sep 30 2021 | n/a | n/a | AU$24m |
| Jun 30 2021 | AU$5m | AU$2m | AU$25m |
| Mar 31 2021 | n/a | n/a | AU$23m |
| Dec 31 2020 | n/a | n/a | AU$21m |
| Sep 30 2020 | n/a | n/a | AU$18m |
| Jun 30 2020 | AU$3m | AU$2m | AU$15m |
| Mar 31 2020 | n/a | n/a | AU$15m |
| Dec 31 2019 | n/a | n/a | AU$15m |
| Sep 30 2019 | n/a | n/a | AU$16m |
| Jun 30 2019 | AU$1m | AU$894k | AU$18m |
| Mar 31 2019 | n/a | n/a | AU$17m |
| Dec 31 2018 | n/a | n/a | AU$16m |
| Sep 30 2018 | n/a | n/a | AU$15m |
| Jun 30 2018 | AU$2m | AU$818k | AU$13m |
| Mar 31 2018 | n/a | n/a | AU$10m |
| Dec 31 2017 | n/a | n/a | AU$6m |
| Sep 30 2017 | n/a | n/a | AU$7m |
| Jun 30 2017 | AU$2m | AU$787k | AU$7m |
Compensación vs. Mercado: La compensación total de Philippe($USD4.12M) está por encima de la media de empresas de tamaño similar en el mercado Australian ($USD769.02K).
Compensación vs. Ingresos: La compensación de Philippe ha sido consistente con los resultados de la empresa en el último año.
CEO
Philippe Wolgen (60 yo)
18.5yrs
Permanencia
AU$6,390,101
Compensación
Dr. Philippe Jacques Wolgen, MBA, M.D., has been the Chief Executive Officer and Managing Director of Clinuvel Pharmaceuticals Limited since November 28, 2005 to lead the corporate turnaround of the Group....
Equipo directivo
| Nombre | Posición | Permanencia | Compensación | Propiedad |
|---|---|---|---|---|
| CEO, MD & Director | 18.5yrs | AU$6.39m | 6.84% A$ 50.9m | |
| CFO & Company Secretary | 18.4yrs | AU$3.09m | 0.36% A$ 2.7m | |
| Chief Scientific Officer | 11.7yrs | AU$636.85k | 0.31% A$ 2.3m | |
| Director of Global Operations | no data | sin datos | sin datos | |
| Head of Australian Operations & Investor Relations | no data | sin datos | sin datos | |
| Senior Vice President of Regulatory Affairs | less than a year | sin datos | sin datos | |
| Head of Quality & Drug Safety | less than a year | sin datos | sin datos |
11.7yrs
Permanencia media
Equipo directivo experimentado: El equipo directivo de CUV es experimentado (11.6 años antigüedad media).
Miembros de la Junta
| Nombre | Posición | Permanencia | Compensación | Propiedad |
|---|---|---|---|---|
| CEO, MD & Director | 18.6yrs | AU$6.39m | 6.84% A$ 50.9m | |
| Non-Executive Director | 17.3yrs | AU$85.00k | 0.23% A$ 1.7m | |
| Non-Executive Director | 4.7yrs | AU$75.00k | 0.00084% A$ 6.3k | |
| Non-Executive Chairman | 4.5yrs | AU$75.00k | 0.0063% A$ 46.8k | |
| Non-Executive Director | 6.3yrs | AU$75.00k | 0.011% A$ 81.8k |
6.3yrs
Permanencia media
Junta con experiencia: La junta directiva de CUV se considera experimentada (7.8 años de antigüedad promedio).